A worldwide biopharmaceutical company.

‘We were holding well-designed studies across a wide dose range that allow us to understand the entire potential of inhibiting this pathway,’ said Mark Genovese, M.D., professor of medication, Stanford University Medical Center, Division of Immunology and Rheumatology. ‘The regularity of response and the overall protection profile of ABT-494 in these two patient populations offer the potential for significant benefit and support advancing this compound into Phase 3 studies.This second trial will employ a narrower selection of single infusion doses to assess safety, various measures of efficacy, including changes in ejection fraction and cardiovascular stamina, and whether there is proof interaction with other medications commonly used in heart failure. Related StoriesProtein sensor for proprioception foundDeaths from avoidable risk elements: an interview with Dr Ali Mokdad, IHMEBrain health: how will you decrease cognitive decline? An interview with Heather Snyder, Ph.D. Results of the initial Phase 1 GGF2 scientific trial were presented earlier this season at the American College of Cardiology 62nd Annual Scientific Program. The trial style included seven cohorts of six participants each, four of whom received GGF2 and two of whom received placebo at each dose.